Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.44 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22921868 | 0.92 | TSHR (0.58) | CYP4A11CYP4F2TSHREPHX2ALOX5 | |
| SCHEMBL3409184 | 0.89 | CYP4A11 (0.68) | CYP4A11CYP4F2TSHREPHX2ALOX5 | |
| SCHEMBL1410420 | 0.89 | CYP4A11 (0.56) | CYP4A11CYP4F2TSHREPHX2ALDH1A1 | |
| SCHEMBL1928824 | 0.85 | PLAAT3 (0.51) | CYP4A11CYP4F2TSHREPHX2ALOX5 | |
| SCHEMBL1863579 | 0.85 | CALM1 (0.55) | CYP4A11CYP4F2TSHREPHX2ALDH1A1 | |
| SCHEMBL13061462 | 0.85 | TSHR (0.50) | CYP4A11CYP4F2TSHREPHX2ALDH1A1 | |
| SCHEMBL26239913 | 0.85 | ALDH1A1 (0.55) | CYP4A11CYP4F2TSHREPHX2ALDH1A1 | |
| SCHEMBL12508639 | 0.85 | TSHR (0.50) | CYP4A11CYP4F2TSHREPHX2ALOX5 | |
| SCHEMBL1866015 | 0.85 | CYP4A11 (0.50) | CYP4A11CYP4F2TSHREPHX2ALOX5 | |
| SCHEMBL10583619 | 0.85 | TSHR (0.50) | CYP4A11CYP4F2TSHREPHX2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253333-B1 | Contrast Agents for Myocardial Perfusion Imaging | LANTHEUS MEDICAL IMAGING INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-2253333-B1 | Contrast Agents for Myocardial Perfusion Imaging | LANTHEUS MEDICAL IMAGING INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1740225-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1740225-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105159-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | CITIZENS BANK, N.A. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885TSHR 2215/4885 |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885TSHR 2215/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | CYP4A11 4708/4885CYP4F2 3563/4885TSHR 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.